Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
KarXT
acetylcholine
and xanomeline
antipsychotic
muscarinic
schizophrenia
Journal
Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
received:
17
11
2023
revised:
08
03
2024
accepted:
17
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
Achieving optimal treatment outcomes for individuals living with schizophrenia remains challenging, despite 70 years of drug development efforts. Many chemically distinct antipsychotics have been developed over the past seven decades with improved safety and tolerability but with only slight variation in efficacy. All currently prescribed antipsychotics act as antagonists or partial agonists at the dopamine D
Identifiants
pubmed: 38537670
pii: S0006-3223(24)01173-9
doi: 10.1016/j.biopsych.2024.03.014
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.